Assetmark, Inc Atreca, Inc. Transaction History
Assetmark, Inc
- $30.5 Billion
- Q1 2024
A detailed history of Assetmark, Inc transactions in Atreca, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 38 shares of BCEL stock, worth $3. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38Holding current value
$3% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BCEL
# of Institutions
9Shares Held
1.04MCall Options Held
0Put Options Held
0-
Bill & Melinda Gates Foundation Seattle, WA913KShares$82,1370.09% of portfolio
-
Xtx Topco LTD London, X054.1KShares$4,8660.0% of portfolio
-
Acadian Asset Management LLC Boston, MA44.1KShares$3,9690.0% of portfolio
-
Gofen & Glossberg LLC20KShares$1,8000.0% of portfolio
-
Endurance Wealth Management, Inc.10.6KShares$9540.0% of portfolio
About Atreca, Inc.
- Ticker BCEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,876,000
- Market Cap $2.87M
- Description
- Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...